Abbott Will Spin Off Its $8.5 Billion Nutrition Business, Home to Ensure and Similac

Abbott plans to separate Ensure, Similac, PediaSure, Pedialyte and Glucerna into a standalone public company by the end of 2027.

Abbott plans to separate Ensure, Similac, PediaSure, Pedialyte and Glucerna into a standalone public company by the end of 2027.